Many currently marketed drugs exert their pharmacological effects by binding to ligand-activated transcription factors and modulating gene expression. One example, are various drugs that target the estrogen receptor to treat breast cancer, osteoporosis and post-menopausal symptoms. Below is a ChIP experiment examining the effects of no drug treatment (C), the natural hormone estrogen (E) and the drugs tamoxifen (T) and raloxifene (R) on recruitment of coactivators (SRC-1 and CBP), Histone Deacetylase Complexes (HDACs) and acetylation of histones associated with the C-myc gene. Which of the following statements are correct based on this data (select all that apply)? BreastUterusERaSRC-1C No DrugE EstrogenT TamoxifenR RaloxifeneHDAC2HDAC4CETRCETR CETRCETRСВРACHCETRCETRA. Tamoxifen represses C-myc expression in both breast and uterusB.Estrogen promotes acetylation of histones in both the breast and uterus which results in increased expression of C-mycgene.C. Raloxifene promotes deacetylation of histones which would inhibit expression of C-myc in both breast and uterus.D.Tamoxifen promotes binding of SRC to C-myc promoter in the uterus which will enhance transcription of C-myc in theuterusE.Estrogen promotes binding of CBP in both the breast and uterus which results in increased expression of C-myc gene.

The image provided shows the results of a ChIP experiment examining the effects of various…

Many currently marketed drugs exert their pharmacological effects by binding to ligand-activated transcription factors and modulating gene expression. One example, are various drugs that target the estrogen receptor to treat breast cancer, osteoporosis and post-menopausal symptoms. Below is a ChIP experiment examining the effects of no drug treatment (C), the natural hormone estrogen (E) and the drugs tamoxifen (T) and raloxifene (R) on recruitment of coactivators (SRC-1 and CBP), Histone Deacetylase Complexes (HDACs) and acetylation of histones associated with the C-myc gene. Which of the following statements are correct based on this data (select all that apply)?

Many currently marketed drugs exert their pharmacological effects by binding to ligand-activated transcription factors and modulating gene expression. One example, are various drugs that target the estrogen receptor to treat breast cancer, osteoporosis and post-menopausal symptoms. Below is a ChIP experiment examining the effects of no drug treatment (C), the natural hormone estrogen (E) and the drugs tamoxifen (T) and raloxifene (R) on recruitment of coactivators (SRC-1 and CBP), Histone Deacetylase Complexes (HDACs) and acetylation of histones associated with the C-myc gene. Which of the following statements are correct based on this data (select all that apply)?

Similar questions

The G-protein Ras is involved in proliferative signaling, and is mutated is a large fraction of human cancers. Almost all mutations in Ras mutate the glycine at codon 12. These mutations lock Ras in an active conformation. How will the GTPase activity of a Ras protein with a G12 mutation compare to a normal Ras protein without the mutation? (10 words maximum)
You have developed an activator of a non-receptor tyrosine kinase. In three different cell types that all contain this receptor your drug has different effects. In cell type A you see activation of gene X and gene Y; in cell type B you note activation of Gene X, but no change in the mRNA levels for Gene Y. In cell type C your drug has no effect on either Gene X or Y. Describe how could each choice (A-D) be a possibility to suit the scenario? a. Genes X & Y are controlled by two separate STATs (STAT X & STAT Y). Cell type A contains both STATs; cell type B contains STAT X only; cell type C has neither STAT. b. Genes X & Y are controlled by two separate STATs (STAT X & STAT Y) and two separate JAKs (JAK X & JAK Y). Cell type A contains both STATs and JAKs; cell type B contains both STATs but JAK X only; cell type C has both STATs but neither JAK. c. Genes X & Y are controlled by two separate STATs (STAT X & STAT Y), two separate JAKs (JAK X & JAK Y) and…
Mutation in the fibroblast growth factor receptor (FGFR) gene results in achondroplasia (dwarfism), which is a dominant condition caused by a single base substitution (GGG>AGG) that changes the amino acid glycine at position 480 to arginine (G480R) in the FGFR protein. FGFR is normally active when FGF binds to it, but the mutant FGFR is always on to stimulate signaling that inhibits excessive bone growth. How can gene therapy be used to treat achondroplasia? Select all that apply. RNAi that knocks down the mutant FGFR expression Adeno-associated viral (AAV) vector that carries the wild-type FGFR Retroviral vector that carries the wild-type FGFR CRISPR with the wild-type FGFR donor DNA
Explain, in detail, how tyrosine kinase proteins are involved in one signal transduction pathway of your choice. Make sure you describe the complete pathway in which it is involved. Then, describe how you would experimentally demonstrate the requirement of a tyrosine kinase protein in your chosen pathway.
If we knock out a gene, it can tell us something about how important that gene is or if other genes can compensate for its absence in a complex. To further establish the role of PSEN1 and PSEN2 in early onset Alzheimer's disease they are individually knocked out in mouse models. Knockout of PSEN1 leads to an embryonic lethal phenotype and dramatically reduced Aß levels. However knockout of PSEN2 gives no obvious phenotype and essentially normal AB levels. Question 16) Which of the following hypotheses does this observation support? [10 Marks] Under normal circumstances y-secretase complexes contain equal ratios of PSEN1 and PSEN2 b. The knockout of PSEN1 and PSEN2 didn't work O c. a. Under normal circumstances y-secretase complexes primarily contain PSEN2 rather than PSEN1 d. Under normal circumstances y-secretase complexes primarily contain PSEN1 rather than PSEN2 e. Under normal circumstances y-secretase complexes do not contain either PSEN1 or PSEN2